Mirum Pharmaceuticals Inc (MIRM)vsMerck & Company Inc (MRK)
MIRM
Mirum Pharmaceuticals Inc
$93.48
+1.07%
HEALTHCARE · Cap: $6.06B
MRK
Merck & Company Inc
$119.60
+0.88%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11446% more annual revenue ($65.77B vs $569.61M). MRK leads profitability with a 13.6% profit margin vs -140.2%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MIRM
Avoid30
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.6%
Fair Value
$190.76
Current Price
$93.48
$97.28 discount
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$119.60
$38.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 43.3% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Elevated debt levels
Trading at 23.5x book value
ROE of -329.4% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 43.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.51 — expect wider price swings.
MIRM is growing revenue faster at 43.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 30/100). MIRM offers better value entry with a 47.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?